– USA, MA – Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced the appointment of Dr. Meeta Chatterjee (Ph.D.) to its board of directors, bringing more than 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities.
“I am pleased to welcome Dr. Chatterjee to our board of directors at this exciting time for our company,” said co-founder and Board Chairman, Dr. Luke Evnin. “Meeta’s deep and proven experience across biopharmaceutical R&D, operations, corporate strategy and business development represents a critical addition to our board’s skill set.”
About Dr. Meeta Chatterjee
Dr. Chatterjee is SVP of Global Business Development at Legend Biotech Corporation. Before this current role at Legend Biotech Corporation, she served as Head of Strategy, Transactions, and Operations within the Business Development and Licensing (BD&L) group at Merck Research Labs, where she oversaw the discovery and late-stage transactions worldwide, as well as early-stage transactions in key geographies, and was responsible for Merck’s BD&L governance, oversight, and control as well as out-licensing efforts. Dr. Chatterjee has led or contributed to several transactions or collaborations, has led research efforts in the areas of hypertension, atherosclerosis, and obesity, and was an integral contributor to the discovery of ZETIA and ZONTIVITY.
“I am thrilled to join Werewolf’s board of directors as the company prepares to advance investigational new drug applications for its two lead INDUKINETM product candidates, WTX-124 and WTX-330, for the treatment of solid tumors,” commented Dr. Chatterjee. “We are just beginning to understand the power of the PREDATORTM protein engineering platform and its potential to generate a broad pipeline of systemically delivered, conditionally activated molecules that may stimulate immunity and provide potentially safer and more efficacious treatments for cancer patients.”
Dr. Chatterjee completed her undergraduate education at St. Xavier’s University in Ahmedabad, India, and Rutgers University (B.A., Honors Physics), received her Ph.D. in Physiology from Rutgers University, and completed a postdoctoral fellowship in the Department of Physiology at the University of Virginia School of Medicine. Dr. Chatterjee is active in industry and licensing-focused organizations.
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity to address the limitations of conventional proinflammatory immune therapies. Our INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. We are continuing preclinical studies for both WTX-124 and WTX-330 and expect to advance each candidate in multiple tumor types as a single agent and combination with an immune checkpoint inhibitor.
For more information: https://werewolftx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
